Hypertrophic cardiomyopathy or HCM is a primary myocardial disorder defined by left ventricular (LV) hypertrophy that cannot be explained by another cardiac or systemic disease. People with HCM face a risk of death more than 3 times greater than the average person of the same age without HCM.
Patients diagnosed with HCM are at increased risk for developing atrial fibrillation, suffering from stroke and even sudden cardiac arrest. It is estimated that 1 in every 500 people have HCM, but a large percentage of patients are undiagnosed. Learning more about HCM will ensure you are better able to discuss its impact with your patients.
HCM Webinar Series @Model.Item.RenderHeadingSizeTag("h2")>
With your help, patients whose lives have been restricted due to HCM may be able to reduce symptoms and comorbidities. Register today and increase your knowledge of the latest HCM science.
HCM Podcast Series @Model.Item.RenderHeadingSizeTag("h2")>
Enhance and expand your understanding of hypertrophic cardiomyopathy so you are better able to discuss its impact with your patients. Listen, learn, and increase your knowledge of the latest HCM science.
Guidelines into Practice: Hypertrophic Cardiomyopathy
Enhance your awareness, knowledge and applicability of guidelines as applied to your interactions with cardiovascular disease and stroke patients with this online CME/CE program. It includes enduring materials based upon highlights of the Hypertrophic Cardiomyopathy guidelines, case studies to illustrate patient applicability and other resource materials.
Guidelines and Articles
- Gersh BJ, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761-2796.
- Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives Evidence for a Change in Paradigm. Circulation, June 2020.
- Cardiomyopathy in Children: Classification and Diagnosis. Circulation, June 2020.
- Maron BJ. Hypertrophic Cardiomyopathy. Circulation. 2002;106:2419-2421.
When patients present with symptoms such as fatigue, fainting, shortness of breath, chest pain or heart palpitations without a known cause, suspect and test for HCM. With your help, patients whose lives have been restricted due to HCM may be able to reduce symptoms and comorbidities.
2018 Prevention Guidelines Tool CV Risk Calculator
This risk calculator tool is used to calculate your patients’ risk for heart disease and stroke using the 2018 ACC/AHA guidelines.
American Heart Association's Hypertrophic Cardiomyopathy Initiative is sponsored by MyoKardia, Inc.